Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $94.9 million.

  • Tonix Pharmaceuticals Holding's Cash from Financing Activities rose 12109.54% to $94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.5 million, marking a year-over-year increase of 16599.1%. This contributed to the annual value of $134.9 million for FY2024, which is 26934.03% up from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Cash from Financing Activities is $94.9 million, which was up 12109.54% from $11.0 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Cash from Financing Activities high stood at $94.9 million for Q3 2025, and its period low was -$11.5 million during Q1 2023.
  • Its 3-year average for Cash from Financing Activities is $29.7 million, with a median of $11.0 million in 2025.
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Cash from Financing Activities showed a top increase of 2346462.26% in 2025 and a maximum decrease of 5648.4% in 2025.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Cash from Financing Activities stood at $40.7 million in 2023, then skyrocketed by 109.15% to $85.2 million in 2024, then grew by 11.4% to $94.9 million in 2025.
  • Its Cash from Financing Activities was $94.9 million in Q3 2025, compared to $11.0 million in Q2 2025 and $49.5 million in Q1 2025.